Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
OnabotulinumtoxinA (Botox)
Treatment for Migraine
Typical Dosage: 155 units injected across 31 sites
Effectiveness
72%
Safety Score
65%
Clinical Trials
63
Participants
9K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
155 units injected across 31 sites
Time to Effect
2-4 weeks
Treatment Duration
Long-term (every 12 weeks)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$4,000
Monitoring:$600
Side Effect Mgmt:$200
Total Annual:$4,800
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$100,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$10,000
Cost per Remission
$40,000
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
4 active trials recruiting for OnabotulinumtoxinA (Botox) in Migraine
COACT Study: CGRPmAbs + OnabotulinumtoxinA Assessment of Chronic Migraine Treatments Study
NCT05724771ACTIVE NOT RECRUITINGPHASE4
50 participants
INTERVENTIONAL
Chicago, United States
Started: Jan 26, 2023
BOTOX® vs. XEOMIN® for Chronic Migraine
NCT05598723RECRUITINGPHASE3
128 participants
INTERVENTIONAL
Jacksonville, United States
Started: Feb 24, 2023
OnaBotulinumtoxin-A in Chronic Migraine Patients With Short or Long Disease History (the BACH Study)
NCT06537700RECRUITING
115 participants
OBSERVATIONAL
Ancona, Italy +5 more
Started: Jan 1, 2024
Botulinum Toxin and/or Greater Occipital Nerve Block for Patients With Chronic Migraine
NCT07535723NOT YET RECRUITINGNA
90 participants
INTERVENTIONAL
Al Fayyum, Egypt
Started: Apr 1, 2026
Completed Clinical Trials
11 completed trials for OnabotulinumtoxinA (Botox) in Migraine
Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population
NCT03055767COMPLETEDPHASE2
17 participants
INTERVENTIONAL
Irvine, United States +1 more
Started: Mar 1, 2017
Calcitonin Gene-related Peptide Levels in Chronic Migraine
NCT01071096COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Springfield, United States +1 more
Started: Jun 1, 2010
Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)
NCT01833130COMPLETEDPHASE4
52 participants
INTERVENTIONAL
San Francisco, United States
Started: Apr 1, 2013
Efficacy of OnabotulinumtoxinA in Migraine
NCT04578782COMPLETEDPHASE2
32 participants
INTERVENTIONAL
Pavia, Italy
Started: Mar 13, 2018
A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine
NCT01516892COMPLETEDPHASE4
716 participants
INTERVENTIONAL
Scottsdale, United States +31 more
Started: Dec 1, 2011
Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine
NCT02037425COMPLETEDPHASE4
44 participants
INTERVENTIONAL
Springfield, United States
Started: Apr 1, 2014
A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency
NCT01700387COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Springfield, United States
Started: Oct 1, 2012
Onabotulinumtoxin Type A Reconstitution With Preserved Versus Preservative-free Saline in Chronic Migraine.
NCT03698409COMPLETEDPHASE4
68 participants
INTERVENTIONAL
Syracuse, United States
Started: Jan 1, 2019
Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®
NCT02502123COMPLETED
215 participants
OBSERVATIONAL
Calgary, Canada +14 more
Started: Jul 2, 2015
(Botox) Mechanisms of Action in Altering the Molecular Environment in Which Pain Fibers Exist
NCT03381261COMPLETEDPHASE4
37 participants
INTERVENTIONAL
Boston, United States
Started: Dec 1, 2017
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
NCT05216263COMPLETEDPHASE3
75 participants
INTERVENTIONAL
Hoover, United States +28 more
Started: Mar 22, 2022
Showing 20 of 65 total trials